Effect of Dietary Phospholipids on Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Dietary Supplement: milk phospholipidDietary Supplement: diary product
- Registration Number
- NCT01326520
- Lead Sponsor
- University of Jena
- Brief Summary
The aim of the study is to investigate the influence of a milk phospholipid enriched dairy product on subjects with atopic dermatitis determining parameters of the immune status, the plasma lipid profile and the skin texture.
- Detailed Description
Based on the facts, that on the one hand milk phospholipids are characterized by a high sphingolipid content and on the other hand a disturbed sphingolipid metabolism in the epidermis of patients with atopic dermatitis was verified, a double blinded, controlled, randomized, cross-over study with a daily supplementation of 3 g milk phospholipids to subjects with a mild to moderate atopic dermatitis will be conducted.
Forty patients will be randomized between two groups of each 20 patients. After an individual checkup and a run-in period of 2 weeks, the one group will receive the phospholipid enriched dairy product and the second group will be given a placebo dairy product over two month. A wash out-period of 4 weeks will follow, and the patients will consume the contrary dairy products over two month after a 2-week run-in period again.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
- mild to moderate atopic dermatitis (SCORAD < 30)
- age: 18 - 60 years
- intolerance against milk proteins
- systemic medication with corticosteroids or antihistamines
- immune mediated disease
- atherosclerosis
- hyperlipidaemia
- diabetes mellitus
- angina pectoris
- adipositas
- pregnancy and breast feeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Phospholipid enriched dairy product milk phospholipid - dairy product diary product -
- Primary Outcome Measures
Name Time Method Change in skin texture from baseline and in comparison with placebo after 0,2,10,16, and 24 weeks SCORAD Index
- Secondary Outcome Measures
Name Time Method Immune status after 0,2,10,16, and 24 weeks total IgE, specific IgE, sE selectin, Interferon-gamma, Tumor necrosis factor-alpha, Interleukin 4, 12, 16, 31
Lipid status after 0,2,10,16, and 24 weeks Blood lipids (Total cholesterol, LDL cholesterol, HDL cholesterol, triacyl glycerdies, fatty acids, phospholipids)
Trial Locations
- Locations (1)
Friedrich Schiller University Jena, Department of Nutritonional Physiology
🇩🇪Jena, Thuringia, Germany